Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder

Biological Psychiatry

Volumn 47, Issue 6, 1999, Pages 475-481

  Winsberg, Mirène E ^a   Sachs, Nadia ^a   Tate, Debbie L ^a   Adalsteinsson, Elfar ^a   Spielman, Daniel ^a   Ketter, Terence A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1H MRS; Bipolar disorder; Dorsolateral prefrontal region; N acetyl aspartate

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; INOSITOL; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; NERVE CELL NETWORK; NERVE FIBER; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ADULT; ASPARTIC ACID; BIPOLAR DISORDER; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PREFRONTAL CORTEX;

EID: 0342723779     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00183-3     Document Type: Article

References (25)

1. Annett M. A classification of hand preferences by association analysis. Br J Psychol. 61:1970;303-321.
2. Bertolino A., Nawroz S., Mattay V.S., et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 153:1996;1554-1563.
3. Dager S.R., Steen G.R. Applications of magnetic resonance spectroscopy to the investigation of neuropsychiatric disorders. Neuropsychopharmacology. 6:1992;249-266.
4. Deicken R.F., Zhou L., Schuff N., Fein G., Weiner M.W. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry. 43:1998;483-488.
5. Ende G, Knowlton RC, Laxer KD, Matson GB, Weiner MW (1996): NAA is a more sensitive marker of hippocampal disease than atrophy: Evidence that NAA is a neuronal marker (abstract). In: Proceedings of the International Society for Magnetic Resonance in Medicine: Fourth Scientific Meeting, Vol 1, 137.
6. George M.S., Ketter T.A., Post R.M. Prefrontal cortex dysfunction in clinical depression. Depression. 2:1994;59-72.
7. 1H nuclear magnetic resonance spectroscopic imaging of neuronal loss in rat brain. Neuroscience. 69:1995;1095-1101.
8. Howe F.A., Maxwell R.J., Saunders D.E., Brown M.M., Griffiths J.R. Proton spectroscopy in vivo. Magn Reson Q. 9:1993;31-59.
9. Kato T., Hamakawa H., Shioiri T., et al. Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder. J Psychiatry Neurosci. 21:1996;248-254.
10. Kato T., Takahashi S., Shioiri T., Murashita J., Hamakawa H., Inubushi T. Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord. 31:1994;125-133.
11. Keshavan M.S., Kapur S., Pettegrew J.W. Magnetic resonance spectroscopy in psychiatry potential, pitfalls, and promise . Am J Psychiatry. 148:1991;976-985.
12. Ketter T.A., George M.S., Kimbrell T.A., Benson B.E., Post R.M. Functional brain imaging, limbic function, and affective disorders. The Neuroscientist. 2:1996;55-65.
13. Lafer B., Renshaw P.F., Sachs G., et al. Proton MRS of the basal ganglia in bipolar disorder (abstract). Biol Psychiatry. 35:1994;685.
14. 1H NMR spectroscopy N-acetyl-L-aspartate, creatine and choline . NMR Biomed. 4:1991;47-52.
15. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E., Lim K.O. In vivo spectroscopic quantification of the N-acetyl moiety, creatine, and choline from large volumes of brain gray and white matter Effects of normal aging . Magn Reson Med. 41:1999;276-284.
16. Rajkowska G., Miguel-Hidalgo J.J., Wei J., et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 45:1999;1085-1098.
17. Renshaw P.F., Lafer B., Babb S.M., et al. Basal ganglia choline levels in depression and response to fluoxetine treatment an in vivo proton magnetic resonance spectroscopy study . Biol Psychiatry. 41:1997;837-843.
18. Renshaw P.F., Yurgelun-Todd D.A., Tohen M., Gruber S., Cohen B.M. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am J Psychiatry. 152:1995;444-446.
19. Sharma R., Venkatasubramanian P.N., Barany M., Davis J.M. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res. 8:1992;43-49.
20. Stoll A.L., Renshaw P.F., De Micheli E., Wurtman R., Pillay S.S., Cohen B.M. Choline ingestion increases the resonance of choline-containing compounds in human brain an in vivo proton magnetic resonance study . Biol Psychiatry. 37:1995;170-174.
21. Stoll A.L., Renshaw P.F., Sachs G.S., et al. The human brain resonance of choline-containing compounds is similar in patients receiving lithium treatment and controls an in vivo proton magnetic resonance spectroscopy study . Biol Psychiatry. 32:1992;944-949.
22. Tsai G., Coyle J.T. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol. 46:1995;531-540.
23. Urenjak J., Williams S.R., Gadian D.G., Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci. 13:1993;981-989.
24. Webb P., Macovski A. Rapid, fully-automatic, arbitrary volume, in-vivo shimming. Magn Reson Med. 20:1991;113-122.
25. 1H spectroscopy of the temporal lobes in schizophrenic and bipolar patients (abstract). In: Proceedings of the Society of Magnetic Resonance in Medicine: Twelfth Annual Scientific Meeting, Vol 3, 1539.